Skip to content

프랭클린템플턴 사칭 유의안내

최근 SNS를 통해 프랭클린템플턴을 사칭하여 코인 사기를 치는 사례가 발생하고 있습니다.
당사 및 임직원은 웹사이트, 전화, 이메일, 우편 및 소셜미디어(오픈톡, 리딩방 등)를 통해 투자상담이나 금융거래를 권유하지 않습니다.
투자자 여러분께서는 이러한 사이버 범죄 피해를 입지 않도록 각별히 주의하시기 바라며, 의심스러운 사항이나 문의사항이 있으시면 아래에 기재된 피해 신고 센터로 연락하시기 바랍니다

무등록 투자자문·일임업 관련
   금융감독원 유사투자자문 피해신고(유사투자자문업자의 경우)
1. 금감원 홈페이지(www.fss.or.kr) ➤ 「민원·신고」 ➤ 「불법금융신고센터」 ➤ 「유사투자자문피해신고」
2. 전화 신고: (02) 3415-7692, 7632, 7633

금융감독원 신고센터 전화 1332

경찰청 사이버범죄 신고시스템(ECRM) 또는 가까운 경찰서(112)
   링크 접속 (https://ecrm.police.go.kr/minwon/main) ➤ 「제보하기」

Innovation can often add value by making existing technologies simpler, smarter or more accessible. From plant-inspired technology to gene therapies that point the way to longer lives to artificial intelligence (AI)-powered World Cup analytics, this quarter's selections spark the imagination. While these breakthroughs span the economy, each introduces fresh ideas to existing industries, often cross-pollinating techniques across disciplines for interesting and unexpected results.

Artificial Plants Offer New Solution to Address Climate Change

Researchers at Osaka Metropolitan University have created an artificial photosynthesis system that mimics the way that plants use sunlight to convert water and carbon dioxide into clean, useable fuel. This simplified system uses a solid electrolyte—a material that conducts charged particles—to automatically adjust energy flow as sunlight changes, offering a potential new path to low-cost clean energy.1

Why it matters: Global carbon dioxide emissions reached roughly 42 billion metric tons of in 2025.2 This technology is exciting because it both consumes carbon dioxide and produces renewable fuel. However, researchers are targeting a 10% energy conversion rate to attain commercial viability, a rate significantly higher than today’s levels.3

Gene Therapy May Make Eye Cells Young Again

Researchers have begun the first human clinical trials of a new gene therapy that aims to rejuvenate aging cells, potentially allowing them to function like younger cells while preserving their identity. This trial targets glaucoma, an eye disease that can cause blindness, with a modified virus that activates three genes in certain eye cells.4

Why it matters: The World Health Organization projects that the global population over age 60 will nearly double by 2050, which would drastically increase the number of age-related illnesses. If cellular reprogramming proves successful, it could open a new approach to treating age-linked diseases by restoring cell function rather than merely slowing their decline.5

New 3D-Printing Manufacturing Method Takes Cues From Origami

Researchers at Oak Ridge National Laboratory have developed a manufacturing process that combines 3D-printing with origami folding. Instead of printing large three-dimensional objects directly, manufacturers print flat composite structures with built-in fold lines that are later folded into complex components. The mostly automated process reduces manufacturing time and eliminates the need for expensive molds.6 

Why it matters: This production method reduces manufacturing time by up to 95%, which translates into potential cost savings of up to 90% while also simplifying transportation. Faster and more flexible production could accelerate innovation across aerospace, automotive and industrial manufacturing to unlock new design possibilities.7

New Brain-Protecting Peptide Targets Parkinson's

Researchers at Brazil’s Federal University of São Paulo identified a naturally occurring peptide, a small protein-like molecule that helps regulate processes in the body, that reduces brain inflammation and protects dopamine-producing neurons in Parkinson’s disease models. Instead of replacing dopamine, the norm in existing therapies, this treatment targets neuroinflammation, which contributes to disease progression.8

Why it matters: Approximately 1.1 million people actively suffer from Parkinson’s in the United States. Current Parkinson’s treatments try to manage symptoms without slowing or preventing progression of the disease. This therapy could represent an important step toward stopping disease progression, compared to treatments that temporarily improve quality of life.9

Metacrystal Panels May Improve Future wireless Networks

Researchers at Aalto University have developed 3D-printed “metacrystals” that act as mirrors for radio waves—redirecting wireless signals around corners, barriers and any obstacle without requiring electronics, a power supply or active tuning. These panels are carefully engineered to improve signals in parking garages, warehouses and office buildings where wireless signals are often blocked by walls, equipment, and other blockades.10

Why this matters: Even though 80% of wireless data traffic happens indoors, less than 2% of commercial buildings have made efforts to better their cellular connection. These metacrystal panels could lower deployment costs by reducing the need for expensive antennas, wiring and other networking equipment while expanding wireless coverage to increase connectivity across the globe.11

AI Joins the Sidelines of the FIFA World Cup

FIFA and tech companies introduced Football AI Pro, a generative AI platform that tracks hundreds of millions of soccer data point to generate tactical insights and interactive visualizations for coaches, including player speed, passing accuracy and defensive positioning. This platform was available to all 48 teams competing in the 2026 FIFA World Cup.12

Why it matters: The sports analytics market, driven by AI, is projected to grow to US$8.4 billion by 2030, according to one source. During the World Cup, coaches used Football AI Pro to simulate how opponents would likely react in certain game scenarios, allowing teams to prepare tailored tactics. Beyond coaching, similar technologies are being adopted for injury prevention, officiating and fan engagement, highlighting how AI is expanding into new industries and transforming the world.13



IMPORTANT LEGAL INFORMATION

This material is provided for general informational purposes only and should not be considered individualized investment advice, a recommendation or a solicitation to adopt any investment strategy. It does not constitute legal or tax advice. Franklin Templeton accepts no liability for losses arising from use of this material.

The views expressed are those of the investment manager as of the publication date and may change without notice. These opinions and analyses are based on certain assumptions, including market conditions that may change. They may differ from those of other portfolio managers or from the firm as a whole.

This material is not intended to provide a complete analysis of all material facts regarding any country, region or market. No assurance can be given that any forecast, projection or prediction regarding economies or financial markets will be realized. References to specific securities are for illustrative purposes only and should not be interpreted as recommendations or a solicitation to buy, sell, or hold any security.

Any research or analysis in this material has been prepared by Franklin Templeton for its own purposes and is provided incidentally. While the information included is believed to be reliable, its accuracy and completeness cannot be guaranteed, and it is subject to change without notice.

Past performance does not guarantee future results, or any profit or gain. All investments involve risks, including possible loss of principal.

Franklin Templeton offers environmental, social and governance (ESG) capabilities, though not all strategies or products incorporate ESG as part of the investment process.

Investment strategies and services may not be available in all jurisdictions. Please consult your financial professional or Franklin Templeton contact for further information.

Brazil: Issued by Franklin Templeton Brasil Ltda. Canada: Issued by Franklin Templeton Investments Corp. Offshore Americas: In the United States, this publication is made available by Franklin Templeton. United States: Issued by Franklin Templeton. Investments are not FDIC insured; may lose value; and are not bank guaranteed.

Europe: Issued by Franklin Templeton International Services S.à r.l., 8A, rue Albert Borschette, L-1246 Luxembourg. Poland: Issued by Templeton Asset Management (Poland) TFI S.A.; Rondo ONZ 1; 00-124 Warsaw.  Saudi Arabia: Issued by Franklin Templeton Financial Company, 13512 Riyadh, Saudi Arabia. Regulated by CMA. License no. 23265-22. South Africa: Issued by Franklin Templeton Investments SA (PTY) Limited, which is authorised by the FSCA as a Financial Service Provider (No.44475). Switzerland: Issued by Franklin Templeton Switzerland Ltd, Talstrasse 41, CH-8001 Zurich. Middle East & Africa (ex South Africa): Issued by Franklin Templeton Investments (ME) Limited, which is regulated by the Dubai Financial Services Authority. Address: Franklin Templeton, The Gate, East Wing, Level 2, Dubai International Financial Centre, P.O. Box 506613, Dubai, U.A.E. Tel: +971(04) 428 4100. United Kingdom: Issued by Franklin Templeton Investment Management Limited (FTIML), registered office: Cannon Place, 78 Cannon Street, London EC4N 6HL.

Australia: Issued by Franklin Templeton Australia Limited (ABN 76 004 835 849) (Australian Financial Services License Holder No. 240827), Level 47, 120 Collins Street, Melbourne, Victoria 3000. Hong Kong: Issued by Franklin Templeton Investments (Asia) Limited. Japan: Issued by Franklin Templeton Japan Co., Ltd. South Korea: Issued by Franklin Templeton Investment Advisors Korea Co., Ltd. Malaysia: Issued by Franklin Templeton Asset Management (Malaysia) Sdn. Bhd. & Franklin Templeton GSC Asset Management Sdn. Bhd. Singapore: Issued by Templeton Asset Management Ltd. (UEN) 199205211E. 2 Central Boulevard, IOI Central Boulevard Towers, West Tower #34-01, Singapore 018916.

Access your local website at www.franklinresources.com/all-sites.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

Copyright © 2026 Franklin Templeton. All rights reserved.